Mostrar el registro sencillo del ítem

dc.contributor.author
Gagliardino, Juan Jose  
dc.contributor.author
Elgart, Jorge Federico  
dc.contributor.author
Forti, Luján  
dc.contributor.author
Guaita, María Silvina  
dc.contributor.author
Chantelot, Jean M.  
dc.date.available
2021-01-11T15:50:22Z  
dc.date.issued
2019-05  
dc.identifier.citation
Gagliardino, Juan Jose; Elgart, Jorge Federico; Forti, Luján; Guaita, María Silvina; Chantelot, Jean M.; Treat-to-target HbA1c and lipid profile to prolong β-cell mass/function and optimize treatment goal attainment; John Wiley & Sons Ltd; Diabetes/metabolism Research and Reviews; 35; 6; 5-2019; 1-7  
dc.identifier.issn
1520-7552  
dc.identifier.uri
http://hdl.handle.net/11336/122250  
dc.description.abstract
Background: To evaluate the relation between different serum lipid fractions and other known barriers to attain the HbA1c ≤ 7.0% (53 mmol/mol) target. Methods: Data on 2719 patients with type 2 diabetes were collected from the five waves of the International Diabetes Mellitus Practice Study implemented in Argentina (2006 to 2012) including demographic/socioeconomic profile, clinical, metabolic (HbA1c and serum lipids) data, and treatment type and also, percentage of treatment goal attainment. Descriptive statistical analyses included ANOVA, χ2 test, and Fisher exact test and univariate and multivariate logistic regression analyses, which identified predictive factors for HbA1c ≤ 7% (53 mmol/mol). Results: The average age was 63 years, primary/secondary education, health insurance, 10‐year type 2 diabetes duration, most associated with cardiovascular risk factors and some microvascular/macrovascular complications; 94.5% received antihyperglycaemic drugs. Percentage of people on target: HbA1c 51.2%, blood pressure 23.5%, total cholesterol 62.6%, low‐density lipoprotein (LDL) cholesterol 38.9%, and triglycerides 61.1%. HbA1c on target depended markedly on treatment type: more of those treated with lifestyle changes and significantly fewer of those receiving insulin. Only 4.1% had all parameters simultaneously on target. Multivariate logistic regression analyses showed that achieving HbA1c ≤ 7.0% (53 mmol/mol) was associated with higher educational level, shorter diabetes duration, and having reached goals for LDL cholesterol and triglycerides, whereas opposite results were obtained with insulin treatment and longer diabetes duration. Conclusions: High LDL cholesterol and triglyceride levels simultaneously potentiate development/progression of chronic complications, exerting this effect in the long term by decreasing β‐cell mass/function, thereby making it more difficult to reach HbA1c values able to prevent complications.  
dc.format
application/pdf  
dc.language.iso
eng  
dc.publisher
John Wiley & Sons Ltd  
dc.rights
info:eu-repo/semantics/openAccess  
dc.rights.uri
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/  
dc.subject
HAEMOGLOBIN A1C  
dc.subject
LDL CHOLESTEROL  
dc.subject
LIPID PROFILES  
dc.subject
Β CELL  
dc.subject
Β-CELL-A1C TARGET  
dc.subject.classification
Endocrinología y Metabolismo  
dc.subject.classification
Medicina Clínica  
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD  
dc.title
Treat-to-target HbA1c and lipid profile to prolong β-cell mass/function and optimize treatment goal attainment  
dc.type
info:eu-repo/semantics/article  
dc.type
info:ar-repo/semantics/artículo  
dc.type
info:eu-repo/semantics/publishedVersion  
dc.date.updated
2020-11-20T17:16:50Z  
dc.journal.volume
35  
dc.journal.number
6  
dc.journal.pagination
1-7  
dc.journal.pais
Reino Unido  
dc.journal.ciudad
Londres  
dc.description.fil
Fil: Gagliardino, Juan Jose. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - La Plata. Centro de Endocrinología Experimental y Aplicada. Universidad Nacional de La Plata. Facultad de Ciencias Médicas. Centro de Endocrinología Experimental y Aplicada; Argentina  
dc.description.fil
Fil: Elgart, Jorge Federico. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - La Plata. Centro de Endocrinología Experimental y Aplicada. Universidad Nacional de La Plata. Facultad de Ciencias Médicas. Centro de Endocrinología Experimental y Aplicada; Argentina  
dc.description.fil
Fil: Forti, Luján. Sanofi Aventis Argentina Sociedad Anonima.; Argentina  
dc.description.fil
Fil: Guaita, María Silvina. Sanofi Aventis Argentina Sociedad Anonima.; Argentina  
dc.description.fil
Fil: Chantelot, Jean M.. Sanofi; Francia  
dc.journal.title
Diabetes/metabolism Research and Reviews  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://onlinelibrary.wiley.com/doi/abs/10.1002/dmrr.3166  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/https://doi.org/10.1002/dmrr.3166